Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control

Giovanni Battista Migliori, Morgan D' Arcy Richardson, Giovanni Sotgiu, Christoph Lange

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The emergence of multidrug-resistant (MDR) and, more recently, of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis is a real threat to achieve tuberculosis (TB) control and elimination globally. More than 510,000 new cases of MDR-TB occur each year and XDR-TB cases are recognized in every setting where there has been the capacity to detect them, particularly in Eastern Europe. MDR- and XDR-TB control in Europe and the United States are heavily affected by what happens globally, as the majority of cases occurring in these countries originate in high TB-burden areas of the world. Scaling-up of culture- and drug susceptibility testing capacities and the expanded use of high-technology assays for rapid determination of resistance represent the prerequisites to achieve better control of MDR- and XDR-TB. Most cases with MDR- and XDR-TB in Europe and the United States can be treated successfully if well-designed regimens based on available second- and third-line anti-TB drugs are used and surgical options are carefully considered. Nevertheless, the development of new (more effective and less toxic) drugs to treat patients infected by MDR- and XDR-TB strains with or without active disease are urgently needed. Adherence to internationally agreed standards of care and control practices is imperative to achieve TB control.

Original languageEnglish
Pages (from-to)637-665
Number of pages29
JournalClinics in Chest Medicine
Volume30
Issue number4
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Extensively Drug-Resistant Tuberculosis
Multidrug-Resistant Tuberculosis
Epidemiology
Tuberculosis
Pharmaceutical Preparations
Eastern Europe
Poisons
Standard of Care
Mycobacterium tuberculosis
Technology

Keywords

  • Epidemiology
  • Europe
  • MDR-TB
  • Surveillance
  • Tuberculosis control
  • United States
  • XDR-TB

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States : Epidemiology, Surveillance, and Control. / Migliori, Giovanni Battista; D' Arcy Richardson, Morgan; Sotgiu, Giovanni; Lange, Christoph.

In: Clinics in Chest Medicine, Vol. 30, No. 4, 12.2009, p. 637-665.

Research output: Contribution to journalArticle

@article{7a1ce36efdb14e51b0e164aad4636aeb,
title = "Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control",
abstract = "The emergence of multidrug-resistant (MDR) and, more recently, of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis is a real threat to achieve tuberculosis (TB) control and elimination globally. More than 510,000 new cases of MDR-TB occur each year and XDR-TB cases are recognized in every setting where there has been the capacity to detect them, particularly in Eastern Europe. MDR- and XDR-TB control in Europe and the United States are heavily affected by what happens globally, as the majority of cases occurring in these countries originate in high TB-burden areas of the world. Scaling-up of culture- and drug susceptibility testing capacities and the expanded use of high-technology assays for rapid determination of resistance represent the prerequisites to achieve better control of MDR- and XDR-TB. Most cases with MDR- and XDR-TB in Europe and the United States can be treated successfully if well-designed regimens based on available second- and third-line anti-TB drugs are used and surgical options are carefully considered. Nevertheless, the development of new (more effective and less toxic) drugs to treat patients infected by MDR- and XDR-TB strains with or without active disease are urgently needed. Adherence to internationally agreed standards of care and control practices is imperative to achieve TB control.",
keywords = "Epidemiology, Europe, MDR-TB, Surveillance, Tuberculosis control, United States, XDR-TB",
author = "Migliori, {Giovanni Battista} and {D' Arcy Richardson}, Morgan and Giovanni Sotgiu and Christoph Lange",
year = "2009",
month = "12",
doi = "10.1016/j.ccm.2009.08.015",
language = "English",
volume = "30",
pages = "637--665",
journal = "Clinics in Chest Medicine",
issn = "0272-5231",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States

T2 - Epidemiology, Surveillance, and Control

AU - Migliori, Giovanni Battista

AU - D' Arcy Richardson, Morgan

AU - Sotgiu, Giovanni

AU - Lange, Christoph

PY - 2009/12

Y1 - 2009/12

N2 - The emergence of multidrug-resistant (MDR) and, more recently, of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis is a real threat to achieve tuberculosis (TB) control and elimination globally. More than 510,000 new cases of MDR-TB occur each year and XDR-TB cases are recognized in every setting where there has been the capacity to detect them, particularly in Eastern Europe. MDR- and XDR-TB control in Europe and the United States are heavily affected by what happens globally, as the majority of cases occurring in these countries originate in high TB-burden areas of the world. Scaling-up of culture- and drug susceptibility testing capacities and the expanded use of high-technology assays for rapid determination of resistance represent the prerequisites to achieve better control of MDR- and XDR-TB. Most cases with MDR- and XDR-TB in Europe and the United States can be treated successfully if well-designed regimens based on available second- and third-line anti-TB drugs are used and surgical options are carefully considered. Nevertheless, the development of new (more effective and less toxic) drugs to treat patients infected by MDR- and XDR-TB strains with or without active disease are urgently needed. Adherence to internationally agreed standards of care and control practices is imperative to achieve TB control.

AB - The emergence of multidrug-resistant (MDR) and, more recently, of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis is a real threat to achieve tuberculosis (TB) control and elimination globally. More than 510,000 new cases of MDR-TB occur each year and XDR-TB cases are recognized in every setting where there has been the capacity to detect them, particularly in Eastern Europe. MDR- and XDR-TB control in Europe and the United States are heavily affected by what happens globally, as the majority of cases occurring in these countries originate in high TB-burden areas of the world. Scaling-up of culture- and drug susceptibility testing capacities and the expanded use of high-technology assays for rapid determination of resistance represent the prerequisites to achieve better control of MDR- and XDR-TB. Most cases with MDR- and XDR-TB in Europe and the United States can be treated successfully if well-designed regimens based on available second- and third-line anti-TB drugs are used and surgical options are carefully considered. Nevertheless, the development of new (more effective and less toxic) drugs to treat patients infected by MDR- and XDR-TB strains with or without active disease are urgently needed. Adherence to internationally agreed standards of care and control practices is imperative to achieve TB control.

KW - Epidemiology

KW - Europe

KW - MDR-TB

KW - Surveillance

KW - Tuberculosis control

KW - United States

KW - XDR-TB

UR - http://www.scopus.com/inward/record.url?scp=71549149666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71549149666&partnerID=8YFLogxK

U2 - 10.1016/j.ccm.2009.08.015

DO - 10.1016/j.ccm.2009.08.015

M3 - Article

C2 - 19925959

AN - SCOPUS:71549149666

VL - 30

SP - 637

EP - 665

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

SN - 0272-5231

IS - 4

ER -